Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
The key words 'dementia', 'Alzheimer's disease' and 'gabapentin' were used. Searches were performed in PubMed, PsycINFO, Ovid MEDLINE, Cochrane Library and ClinicalTrials.gov. The search revealed that there are limited data on the efficacy of gabapentin for BPSD in the form of 11 case reports, 3 case series and 1 retrospective chart review; no Preliminary low-grade evidence based on case series and case reviews suggests possible benefit of gabapentin and pregabalin in patients with BPSD in Alzheimer's disease. These benefits cannot be confirmed until well-powered randomized controlled trials are undertaken. Evidence in frontotemporal dementia is lacking. Gabapentin has been increasingly prescribed to older adults for off-label indications, and accumulating evidence suggests potential for gabapentin misuse and related adverse events. However, the relation between gabapentin initiation and longer-term neurocognitive changes is not well understood. The authors describe the use of gabapentin in the treatment of 4 outpatients with dementia-associated agitation. On the basis of clinical case reports and the Overt Agitation Severity Scale, all 4 patients had reduced agitation with gabapentin. Three of 4 patients were successfully titrated to a full dose of 2,400mg/day. These findings suggest a possible role for gabapentin in the behavioral Objective: Previous studies have shown that gabapentin or pregabalin use is associated with cognitive decline. Herein, we aimed to evaluate the association between gabapentin or pregabalin use and the risk of dementia. Methods: In this retrospective, population-based matched cohort stu Especially in older adults, gabapentin and pregabalin are prescribed to treat behavioral and psychological symptoms of dementia (BPSD). A systematic review analyzing 24 relevant articles found that the use of gabapentinoid agents significantly decreased BPSD in patients with Alzheimer’s disease, suggesting a possible benefit. Among gabapentin users, concurrent use of antidepressants, antipsychotics, or opioids, was common throughout the study period. In addition, up to 39%, 51%, and 64% of gabapentin users with normal cognition, MCI, and dementia concurrently used gabapentin with antidepressants, respectively. The evidence of gabapentin and dementia is mixed, with two studies looking at hundreds of thousands of people and coming to completely different conclusions. The researchers relied on a database maintained by the Quebec health insurance program. From it, they identified nearly 2,000 men and women over age 66 who had been diagnosed with Alzheimer's disease. They randomly selected more than 7,000 others without Alzheimer's who were matched for age and sex to those with the disease. We would like to show you a description here but the site won’t allow us. Gabapentin, commonly prescribed for chronic pain, particularly neuropathic pain, has both analgesic properties (Chincholkar, 2018) and potential neuroprotective benefits (Yan et al., 2019). Its role in the relationship between chronic pain and cognitive outcomes, including dementia, is of growing interest. There is evidence that certain medications — both prescription and over-the-counter — are associated with an increased risk of dementia. The latest study to confirm this connection came out in June 2019 in the Journal of the American Medical Association (JAMA). Although previous studies have established a link between chronic pain and elevated risk of cognitive dysfunction, including dementia (Kao et al., 2021; Chen et al., 2023; Cao et al., 2019), the literature is sparse on gabapentin's potential role in dementia onset. The study data was drawn from the National Alzheimer’s Coordinating Center’s (NACC) Uniform Data Set (UDS) from 2005 to March 2021. NACC was first established in 1999 to aggregate and share data collected at National Institute on Aging-funded Alzheimer’s Disease Research Centers (ADRCs) and conduct research related to AD (Morris et al Methods: We conducted a retrospective cohort study using the National Alzheimer's Coordinating Center Uniform Data Set (UDS; September 2005-March 2021 data freeze). From the eligible sample (≥age 65 years), we identified cognitively normal new-users of gabapentin and the visit they initiated gabapentin (i.e., index visit). However, several case reports in which gabapentin was used for agitation in dementia with Lewy bodies question its appropriateness for all types of dementia-related agitation [14–16]. Indeed, paradoxical gabapentin-induced exacerbation of psychosis in a patient with schizophrenia has already been described [ 17 ]. From the eligible sample (≥age 65 years), we identified cognitively normal new-users of gabapentin and the visit they initiated gabapentin (i.e., index visit). Initiators were matched to randomly selected nonusers on year of UDS enrollment and visit number from enrollment to index. Conclusion: Patients treated with gabapentin or pregabalin had an increased risk of dementia. Therefore, these drugs should be used with caution, particularly in susceptible individuals. Keywords: dementia, Alzheimer disease, cognitive impairment, gabapentin (GBP), pregabalin (PGB) Summary: Dementia alzheimer's type is reported as a side effect among people who take Neurontin (gabapentin), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Aricept, and have Depression. Gabapentin use was significantly associated with decline in cognitive and functional status among older adults with initially normal cognition. Further studies are needed to examine the association.
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |